Log in

ASX:RMDRESMED/IDR UNRESTR Stock Price, Forecast & News

A$25.90
-0.14 (-0.54 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$25.59
Now: A$25.90
A$26.01
50-Day Range
A$25.90
MA: A$25.90
A$25.90
52-Week Range
A$17.31
Now: A$25.90
A$28.21
Volume1.23 million shs
Average Volume1.82 million shs
Market Capitalization$37.47 billion
P/E Ratio73.52
Dividend Yield0.97%
BetaN/A
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides humidifiers, carry bags, and breathing circuits; data communications and control products, such as AirView Diagnostics, EasyCare, ResLink, ResControl, ResControl II, TxControl, ResScan, and ResTraxx modules; U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; and myAir, a patient engagement application that provides sleep data and a daily score based on their previous night's data, as well as offers business management software and services to medical equipment and home health providers. It markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 120 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Read More
RESMED/IDR UNRESTR logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-858-7462400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.89 billion
Cash FlowA$0.24 per share
Book ValueA$1.56 per share

Profitability

Miscellaneous

Employees5,940
Outstanding Shares1,446,680,064
Market Cap$37.47 billion
Next Earnings DateN/A
OptionableOptionable

Receive RMD News and Ratings via Email

Sign-up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.

RESMED/IDR UNRESTR (ASX:RMD) Frequently Asked Questions

How has RESMED/IDR UNRESTR's stock been impacted by COVID-19 (Coronavirus)?

RESMED/IDR UNRESTR's stock was trading at A$23.83 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RMD stock has increased by 8.7% and is now trading at A$25.90. View which stocks have been most impacted by Coronavirus.

How often does RESMED/IDR UNRESTR pay dividends? What is the dividend yield for RESMED/IDR UNRESTR?

RESMED/IDR UNRESTR declared a Interim dividend on Monday, May 4th. Shareholders of record on Thursday, June 18th will be given a dividend of 0.042 per share on Thursday, June 18th. This represents a yield of 0.17%. The ex-dividend date is Wednesday, May 13th. This is a boost from RESMED/IDR UNRESTR's previous Interim dividend of A$0.04. View RESMED/IDR UNRESTR's dividend history.

Has RESMED/IDR UNRESTR been receiving favorable news coverage?

Media headlines about RMD stock have been trending negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. RESMED/IDR UNRESTR earned a news sentiment score of -2.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about RESMED/IDR UNRESTR.

Who are some of RESMED/IDR UNRESTR's key competitors?

What other stocks do shareholders of RESMED/IDR UNRESTR own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RESMED/IDR UNRESTR investors own include CSL (CSL), Altium (ALU), Appen (APX), Abbott Laboratories (ABT), Cochlear (COH), FuelCell Energy (FCEL), Flight Centre Travel Group (FLT), Primary Health Care (PRY), Western New England Bancorp (WNEB) and AbbVie (ABBV).

Who are RESMED/IDR UNRESTR's key executives?

RESMED/IDR UNRESTR's management team includes the following people:
  • Mr. Michael J. Farrell BE, SM, MBA, CEO & Director (Age 47)
  • Mr. Robert A. Douglas, Pres & COO (Age 59)
  • Mr. Brett A. Sandercock, Chief Financial Officer (Age 52)
  • Mr. David B. Pendarvis, Chief Admin. Officer, Global Gen. Counsel & Sec. (Age 60)
  • Mr. James Hollingshead, Pres of Sleep Bus. (Age 56)

What is RESMED/IDR UNRESTR's stock symbol?

RESMED/IDR UNRESTR trades on the ASX under the ticker symbol "RMD."

What is RESMED/IDR UNRESTR's stock price today?

One share of RMD stock can currently be purchased for approximately A$25.90.

How big of a company is RESMED/IDR UNRESTR?

RESMED/IDR UNRESTR has a market capitalization of $37.47 billion and generates $2.89 billion in revenue each year. RESMED/IDR UNRESTR employs 5,940 workers across the globe.

What is RESMED/IDR UNRESTR's official website?

The official website for RESMED/IDR UNRESTR is www.resmed.com.

How can I contact RESMED/IDR UNRESTR?

RESMED/IDR UNRESTR's mailing address is 9001 Spectrum Center Blvd, SAN DIEGO, CA 92123-1438, United States. The company can be reached via phone at +1-858-7462400.

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.